55592-85-3

Basic information

• Product Name: Z-DL-LYS(Z)-OH
• Synonyms: N-ALPHA,N-EPSILON-DI-Z-DL-LYSINE;N-ALPHA-N-EPSILON-DICARBOBENZOXY-DL-LYSINE;N-ALPHA,EPSILON-BIS-Z-DL-LYSINE;Z-DL-LYS(D)-OH;Z-DL-LYSINE(Z)-OH;Z-DL-LYS(Z)-OH;nα,nε-di-z-dl-lysine;N,N''-DICARBOBENZYLOXY-DL-LYSINE)
• CAS NO: 55592-85-3
• Molecular Formula: C₂₂H₂₆N₂O₆
• Molecular Weight: 414.45
• Mol File: 55592-85-3.mol
• Article Data: 4

Chemical Properties

• Melting Point: 90-95 °C(lit.)
• Boiling Point: 659 °C at 760 mmHg
• Flash Point: 352.4 °C
• Appearance: /
• Density: 1.238 g/cm³
• Vapor Pressure: 2.9E-18mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: Store at 0-5°C
• BRN: 2027663
• CAS DataBase Reference: Z-DL-LYS(Z)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: Z-DL-LYS(Z)-OH(55592-85-3)
• EPA Substance Registry System: Z-DL-LYS(Z)-OH(55592-85-3)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 55592-85-3(Hazardous Substances Data)

Usage

General Description

Z-DL-LYS(Z)-OH is a chemical compound that is a derivative of the amino acid lysine. The "Z" in its name indicates that it is a compound with a Z configuration around the double bond. Z-DL-LYS(Z)-OH is commonly used in organic synthesis and pharmaceutical research as a building block for the creation of various drugs and bioactive compounds. It is also often used as a reagent in peptide synthesis and in the production of polypeptides and proteins. Z-DL-LYS(Z)-OH is an important compound in the field of biochemistry and organic chemistry due to its versatile applications in drug development and peptide synthesis.

InChI:InChI=1/C22H26N2O6/c25-20(26)19(24-22(28)30-16-18-11-5-2-6-12-18)13-7-8-14-23-21(27)29-15-17-9-3-1-4-10-17/h1-6,9-12,19H,7-8,13-16H2,(H,23,27)(H,24,28)(H,25,26)

Upstream product

• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 923-27-3 D-lysine 
• 32302-83-3 N-ε-benzyloxycarbonyl lysine 
• 501-53-1 benzyl chloroformate 
• 70-54-2 2,6-diaminocaproic acid 

Downstream Products

• 97485-06-8 (Z)-D-Lys(Z)-OPcp 
• 63628-64-8 Z-Lys(-Z)-Lys(-Z)-OtBu 
• 1375013-89-0 N₂,N₆-bis[(benzyloxy)carbonyl]-D-lysyl-N₆-[(benzyloxy)carbonyl]-N-(4-[(2-tert-butyl-6-methoxyquinolin-8-yl)amino]pentyl)-D-lysinamide 
• 1295647-53-8 [(R)-5-benzyloxycarbonylamino-5-fluorocarbonylpentyl]carbamic acid benzyl ester 
• 69677-06-1 N,N'-Dibenzyloxycarbonyl-(R)-β-homolysin 
• 69677-07-2 [N'-((R)-3,7-Bis-benzyloxycarbonylamino-heptanoyl)-N-methyl-hydrazino]-acetic acid ethyl ester 
• 69677-08-3 [N'-((R)-3,7-Bis-benzyloxycarbonylamino-heptanoyl)-N-methyl-hydrazino]-acetic acid 
• 134915-92-7 4-(4-Benzyloxycarbonylamino-butyl)-2-(1,5-bis-benzyloxycarbonylamino-pentyl)-4,5-dihydro-1H-imidazole-4-carboxylic acid methyl ester 
• 97485-07-9 N^α,N^ε-Bis(benzyloxycarbonyl)-D-lysyl-N^ε-(benzyloxycarbonyl)-D-lysine Methyl Ester 
• 925934-33-4 (R)-{5-benzyloxycarbonylamino-1-[4-(2-tert-butyl-6-methoxy-8-quinolylamino)pentylcarbamoyl]pentyl}carbamic acid benzyl ester 
• 925934-78-7 (R)-{5-benzyloxycarbonylamino-1-[4-(4-ethyl-6-methoxy-5-pentyloxy-8-quinolylamino)pentylcarbamoyl]pentyl}carbamic acid benzyl ester 
• 2766-23-6 N-(N²,N⁶-bis-benzyloxycarbonyl-DL-lysyl)-glycine ethyl ester 
• 69677-05-0 N,N'-Dibenzyloxycarbonyl-(R)-β-homolysinmethylester 

Relevant articles and documents

DRUG-LOADED EMULSION

The present invention relates to a drug-loaded emulsion, comprising a modified hydrophobic excipient having the following formula, a hydrophobic drug and a surfactant: where R is a hydrophobic natural compound or a hydrophobic synthetic compound with one to three hydroxyl groups (n=1-3); and R1 is an α-amino protecting group, and R2 is an amino acid side chain, wherein, when m=0, R is reacted with an amino acid derivative with a protecting group by esterification to form a hydrophobic excipient carrying the amino acid derivative with a protecting group; or when m=1, R is firstly introduced with an amino acid linking arm of different chain lengths (l=1, 2, 4, 6) via an ester group, and then introduced with an amino acid derivative with a protecting group.

Synthesis, screening and docking of small heterocycles as Glycogen Phosphorylase inhibitors

A series of morpholine substituted amino acids (phenylalanine, leucine, lysine and glutamic acid) was synthesized. A fragment-based screening approach was then used to evaluate a series of small heterocycles, including morpholine, oxazoline, dihydro-1,3-oxazine, tetrahydro-1,3-oxazepine, thiazoline, tetrahydro-1,3-pyrimidine, tetrahydro-1,3-diazepine and hexahydro-1H-benzimidazole, as potential inhibitors of Glycogen Phosphorylase a. Thiazoline 7 displayed an improved potency (IC50 of 25 μM) and had good LE and LELP values, as compared to heterocycles 1, 5, 9e13 and 19 (IC50 values of 1.1 mM e23.9 mM). A docking study using the crystal structure of human liver Glycogen Phosphorylase, provided insight into the interactions of heterocycles 5, 7, 9e13 and 19 with Glycogen Phosphorylase.